LT3801526T - 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4- il-7h-imidazo[1,5-a]pirazin-8-ono monohidratas ir kristalų formos - Google Patents

6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4- il-7h-imidazo[1,5-a]pirazin-8-ono monohidratas ir kristalų formos

Info

Publication number
LT3801526T
LT3801526T LTEPPCT/US2019/033835T LTUS2019033835T LT3801526T LT 3801526 T LT3801526 T LT 3801526T LT US2019033835 T LTUS2019033835 T LT US2019033835T LT 3801526 T LT3801526 T LT 3801526T
Authority
LT
Lithuania
Prior art keywords
pyrazin
tetrahydropyran
pyrrolidin
pyrimidin
ylmethyl
Prior art date
Application number
LTEPPCT/US2019/033835T
Other languages
English (en)
Inventor
Suzanne BUTTAR
Mateusz PITAK
Adam Ross PATTERSON
Samuel Alexander STRATFORD
Ioana SOVAGO
Jun Xu
Peng Zhou
Haojuan WEI
Kuangchu DAI
Original Assignee
Cardurion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals, Inc. filed Critical Cardurion Pharmaceuticals, Inc.
Publication of LT3801526T publication Critical patent/LT3801526T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/US2019/033835T 2018-05-25 2019-05-23 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4- il-7h-imidazo[1,5-a]pirazin-8-ono monohidratas ir kristalų formos LT3801526T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676381P 2018-05-25 2018-05-25
US201962788323P 2019-01-04 2019-01-04
PCT/US2019/033835 WO2019226944A1 (en) 2018-05-25 2019-05-23 Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one

Publications (1)

Publication Number Publication Date
LT3801526T true LT3801526T (lt) 2024-04-10

Family

ID=68617192

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/033835T LT3801526T (lt) 2018-05-25 2019-05-23 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4- il-7h-imidazo[1,5-a]pirazin-8-ono monohidratas ir kristalų formos

Country Status (16)

Country Link
US (1) US20210107911A1 (lt)
EP (2) EP3801526B1 (lt)
JP (1) JP2021526134A (lt)
KR (1) KR20210014662A (lt)
CN (2) CN112469413B (lt)
AU (1) AU2019275075A1 (lt)
BR (2) BR112020024019A2 (lt)
CA (1) CA3100988A1 (lt)
DK (1) DK3801526T3 (lt)
FI (1) FI3801526T3 (lt)
IL (1) IL278875A (lt)
LT (1) LT3801526T (lt)
MA (1) MA52792A (lt)
MX (1) MX2020012636A (lt)
PT (1) PT3801526T (lt)
WO (1) WO2019226944A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000507A1 (en) 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2020227399A1 (en) * 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114852A (en) 1994-08-08 2000-02-29 Debiopharm Sa Pharmaceutically stable preparation of oxaliplatinum
ATE365037T1 (de) 2001-03-02 2007-07-15 Debiopharm Sa Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
JP2011513202A (ja) * 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP2015531401A (ja) * 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
RU2657591C2 (ru) 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
JP6431528B2 (ja) 2013-04-10 2018-11-28 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 癌治療のための薬物局所送達装置及び方法
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
TN2017000507A1 (en) * 2015-07-07 2019-04-12 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Also Published As

Publication number Publication date
CN117843645A (zh) 2024-04-09
CN112469413B (zh) 2024-01-12
EP3801526A1 (en) 2021-04-14
FI3801526T3 (fi) 2024-03-20
JP2021526134A (ja) 2021-09-30
US20210107911A1 (en) 2021-04-15
EP3801526A4 (en) 2022-04-06
MA52792A (fr) 2021-04-14
IL278875A (en) 2021-01-31
WO2019226944A1 (en) 2019-11-28
PT3801526T (pt) 2024-03-26
AU2019275075A1 (en) 2021-01-14
CA3100988A1 (en) 2019-11-28
EP4349403A2 (en) 2024-04-10
MX2020012636A (es) 2021-01-29
DK3801526T3 (da) 2024-03-25
EP3801526B1 (en) 2023-12-27
BR112020024019A2 (pt) 2021-02-23
BR122023022641A2 (pt) 2024-02-20
KR20210014662A (ko) 2021-02-09
CN112469413A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
IL258654A (en) Processes for the preparation of (3s,4r)-3-ethyl-4-(3h- imidiazo[1,2-a]pyrrolo[2, 3-e]-pyrazin-8-yl)-n-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide and their solid state forms
EP3268000A4 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
IL284228A (en) imidazo[1,2-b]pyridazine il-17a inhibitors
IL278875A (en) Monohydrate and crystalline forms of 6-[(S4,S3)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo [5,1-A ]pyrazine-8-one
EP3573989A4 (en) CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
EG25081A (en) Use of prolines for improving growth and/or yield.
HK1257071A1 (zh) 作為磷酸二酯酶抑制劑的2-苯基-3，4-二氫吡咯並[2，1-f][1，2，4]三嗪酮衍生物及其用途
EP1945222A4 (en) PYRROLO [2,1-F] [1,2,4] TRIAZIN-4-YLAMINE DERIVATIVES INHIBITORS OF IGF-1R KINASE FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
EP3792263A4 (en) PYRROLO [2,1-F] [1,2,4] DERIVATIVES FOR SELECTIVE HER2 INHIBITORS AND THEIR APPLICATION
EP3666774A4 (en) 1H-PYRAZOLO [4.3-H] QUINAZOLINE COMPOUND FOR USE AS A KINASE PROTEIN INHIBITOR
ZA202208798B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
RS62496B1 (sr) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu
EP3730492A4 (en) COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
EP3939588A4 (en) USES OF PHOSPHODIESTERASE INHIBITORS
AU2021383928A9 (en) Fgfr inhibitors and methods of making and using the same
ZA202208799B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
IL276160A (en) A salt of the compound pyrazolo[5,1-]pyrimidine and its crystals
WO2008157563A3 (en) Deuterium-enriched clopidogrel
EP4040092A4 (en) DOOR BODY AND REFRIGERATOR WITH IT
EP3941909A4 (en) PI4-KINASE INHIBITORS AND METHODS OF USE THEREOF
EP3988544A4 (en) ISOQUINOLINONE DERIVATIVES AS ROCK PROTEIN KINASE INHIBITORS AND THEIR USE
EP3740468A4 (en) SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
EA202092762A1 (ru) МОНОГИДРАТНАЯ И КРИСТАЛЛИЧЕСКАЯ ФОРМЫ 6-[(3S,4S)-4-МЕТИЛ-1-(ПИРИМИДИН-2-ИЛМЕТИЛ)ПИРРОЛИДИН-3-ИЛ]-3-ТЕТРАГИДРОПИРАН-4-ИЛ-7H-ИМИДАЗО[1,5-a]ПИРАЗИН-8-ОНА
AU2017903306A0 (en) DERIVATIVES OF 4-(IMIDAZO[1,2-b]PYRIDAZIN-3-YL) PYRIMIDIN-2-AMINE AND THEIR USE AS INHIBITORS OF PROTEIN KINASES